Nima Farzan - Feb 10, 2023 Form 4/A - Amendment Insider Report for Kinnate Biopharma Inc. (KNTE)

Role: Chief Executive Officer, Director
Signature: /s/ Mark A. Meltz, attorney in fact
Stock symbol: KNTE
Transactions as of: Feb 10, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 2/15/2023, 10:01 AM
Date Of Original Report: Feb 14, 2023
Previous filing: Jun 3, 2022
Next filing: Jun 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Employee Stock Option (right to buy)	Award	$0	+750K		$0.00	750K	Feb 10, 2023	Common Stock	750K	$6.78	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date.

Content

One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date.